Rovelizumab

Rovelizumab is a monoclonal antibody that was developed for the treatment of stroke and acute myocardial infarction. It was designed to target and neutralize interleukin-8, a pro-inflammatory cytokine that plays a crucial role in the pathogenesis of these conditions. However, clinical trials did not show significant benefits and the development of Rovelizumab was discontinued.

History[edit | edit source]

Rovelizumab was developed by the pharmaceutical company Genentech. It was one of the first monoclonal antibodies to be tested in clinical trials for the treatment of stroke and acute myocardial infarction. The development of Rovelizumab began in the late 1990s, with the first clinical trials starting in the early 2000s.

Mechanism of Action[edit | edit source]

Rovelizumab works by binding to interleukin-8, a cytokine that is released in response to tissue damage and inflammation. By neutralizing interleukin-8, Rovelizumab is thought to reduce inflammation and limit the extent of tissue damage following a stroke or heart attack.

Clinical Trials[edit | edit source]

Several clinical trials were conducted to assess the efficacy and safety of Rovelizumab. However, the results were not promising. In a phase II trial for acute myocardial infarction, Rovelizumab did not show significant benefits in terms of reducing the size of the infarct or improving patient outcomes. Similarly, a phase II trial for stroke did not show significant benefits in terms of reducing the extent of brain damage or improving neurological outcomes.

Discontinuation[edit | edit source]

Following the disappointing results of the clinical trials, the development of Rovelizumab was discontinued. The failure of Rovelizumab highlighted the challenges of developing effective treatments for stroke and heart attack, and led to a re-evaluation of the role of interleukin-8 in these conditions.